- Home
- WTM vs AKRO Comparison
WTM vs AKRO Comparison
Compare WTM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTM
- AKRO
- Stock Information
- Founded
- WTM 1980
- AKRO 2017
- Country
- WTM Bermuda
- AKRO United States
- Employees
- WTM N/A
- AKRO N/A
- Industry
- WTM Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- WTM Finance
- AKRO Health Care
- Exchange
- WTM Nasdaq
- AKRO Nasdaq
- Market Cap
- WTM 4.4B
- AKRO 3.6B
- IPO Year
- WTM N/A
- AKRO 2019
- Fundamental
- Price
- WTM $1,754.00
- AKRO $46.20
- Analyst Decision
- WTM
- AKRO Strong Buy
- Analyst Count
- WTM 0
- AKRO 8
- Target Price
- WTM N/A
- AKRO $80.38
- AVG Volume (30 Days)
- WTM 30.6K
- AKRO 978.3K
- Earning Date
- WTM 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- WTM 0.06%
- AKRO N/A
- EPS Growth
- WTM N/A
- AKRO N/A
- EPS
- WTM 79.93
- AKRO N/A
- Revenue
- WTM $2,578,600,000.00
- AKRO N/A
- Revenue This Year
- WTM N/A
- AKRO N/A
- Revenue Next Year
- WTM N/A
- AKRO N/A
- P/E Ratio
- WTM $21.56
- AKRO N/A
- Revenue Growth
- WTM 12.16
- AKRO N/A
- 52 Week Low
- WTM $1,678.87
- AKRO $21.34
- 52 Week High
- WTM $2,023.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- WTM 45.39
- AKRO 51.07
- Support Level
- WTM $1,700.00
- AKRO $41.80
- Resistance Level
- WTM $1,785.77
- AKRO $45.44
- Average True Range (ATR)
- WTM 33.91
- AKRO 1.97
- MACD
- WTM -8.04
- AKRO 0.06
- Stochastic Oscillator
- WTM 38.01
- AKRO 74.58
About WTM White Mountains Insurance Group Ltd.
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.